CMV Adenoviral Expression System

  • Engineered to produce 100- to 10,000-fold fewer wild type plaques than most other expression systems
  • Generate high-titer virus in about 2-3 weeks compared to 2-3 months with other systems
  • Cloning capacity of shuttle vector = 6.9 kb


Frequently Asked Questions about this product

General FAQs about using Adenovirus

General FAQs about Viral Gene Delivery

Email To BuyerPrint this PageCopy Link

Please contact your distributor for pricing.

RAPAd® CMV Adenoviral Expression System
Catalog Number
1 kit
Manual/Data Sheet Download
SDS Download
Map Download
Sequence Download
Product Details

Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification.

The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.

Recent Product Citations
  1. Ansari, S. A. et al. (2016). The role of putative phosphatidylserine-interactive residues of tissue factor on its coagulant activity at the cell surface. PLoS One. doi:10.1371/journal.pone.0158377.
  2. Wang, X. & Astrof, S. (2016). Neural crest cell-autonomous roles of fibronectin in cardiovascular development. Development. 143:88-100.
  3. Bae, E. J. et al. (2015). Cell models to study cell-to-cell transmission of α-synuclein. Methods Mol Biol. 1345:291-298.
  4. Suchanek, A. L. & Salati, L. M. (2015). Construction and evaluation of an adenoviral vector for the liver-specific expression of the serine/arginine-rich splicing factor, SRSF3Plasmid.  doi:10.1016/j.plasmid.2015.07.004.
  5. Wang, S. et al. (2015). Glycoprotein from street rabies virus BD06 induces early and robust immune responses when expressed from a non-replicative adenovirus recombinant. Arch Virol. doi:10.1007/s00705-015-2512-1.
  6. Li, M. et al. (2014). Bisphenol AF-induced endogenous transcription is mediated by ERα and ERK1/2 activation in human breast cancer cells. PLoS One. 9:e94725.
  7. Kim, S. C. et al.  (2014). All‐trans‐retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. Hepatology. 59:1750-1760.
  8. Zheng, H. et al. (2014). Inhibition of Endometrial Cancer by n-3 Polyunsaturated Fatty Acids in Preclinical Models. Cancer Prev Res (Phila). 7:824-834.
  9. Logan, S. et al. (2014). Endoplasmic reticulum microenvironment and conserved histidines govern ELOVL4 fatty acid elongase activity. J. Lipid Res. 55:698-708.
  10. Liu, Q. et al. (2013). Evaluation of Rabies Biologics against Irkut Virus Isolated in China. J. Clin. Microbiol. 51:3499-3504 (#VPK-252).
  11. Logan, S. et al. (2013). Deciphering Mutant ELOVL4 Activity in Autosomal-Dominant Stargardt Macular Dystrophy. PNAS. 110:5446-5451 (#VPK-252).